Disclosed is a time-to-digital converter (TDC)-based device comprising a crossbar array for generating a current, a current-controlled delay line 104 for converting the current received from the crossbar array into a time pulse, and a TDC circuit 106 for measuring and converting the time pulse into digital output.
G04F 10/00 - Apparatus for measuring unknown time intervals by electric means
G04F 10/10 - Apparatus for measuring unknown time intervals by electric means by measuring electric or magnetic quantities changing in proportion to time
2.
METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF
Provided is a method for coupling flavonoid-containing compounds to provide flavonoid dimers, trimers and oligomers. The method comprises contacting a flavonoid-containing compound with base in the presence of air. Flavonoid dimers, trimers and oligomers may also be useful in the treatment of diseases, such as fungal infections and diseases associated with starch hydrolase.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
C07D 311/36 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
Wirelessly powered photodynamic therapy devices are disclosed and systems and methods using such devices are also disclosed. In an embodiment, a photodynamic therapy system comprises: an implantable illumination device comprising a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device; and a transmitter comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate the radiofrequency power signal, and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radiofrequency signal backscattered from the implantable illumination device.
The present invention relates to methods modifying cell surface markers of red blood cells (RBCs) and uses of the same. In particular, the method comprises contacting an RBC with a peptide in the presence of a ligase, under suitable conditions and for sufficient time to allow ligation of the peptide to the RBC to form an RBC-peptide conjugate. In one embodiment, the ligase is OaAEPI ligase. The RBC-peptide conjugate may be further contacted with an effector molecule under suitable conditions and for sufficient time for conjugation of the effector molecule to the RBC-peptide to form an RBC-peptide-effector molecule conjugate.
Disclosed herein is a composite material comprising: a plurality of water-stable metal-organic frameworks, each having a plurality of porous cavities; and a temperature-sensitive polymeric material in the form of polymer chains, wherein the polymer chains of the temperature-sensitive polymeric material are formed at least partly within the porous cavities of the plurality of water-stable metal-organic frameworks. Also disclosed herein is the use of said composite material for adsorption and release of water.
B01D 53/28 - Selection of materials for use as drying agents
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
A method of using a quantum random number generator, QRNG, for security applications, a system for security applications, and a user device for a system for security applications. The method comprises the steps of generating one or more quantum keys using the QRNG; storing, using a secure network, corresponding sets of the quantum keys in a server located at a controlled access location and in a quantum key token, QKT, for a user, respectively; and using the corresponding sets of quantum keys for secure transmission between the server and a user device comprising the QKT when outside the secure network or for access control to the controlled access location.
A thin-film-composite hollow-fiber membrane includes a phase-inversion layer, which is in the form of a hollow fiber, and an active layer coated on the phase-inversion layer. The active layer selectively allows passage of water molecules but rejects at least some dissolved ions. The thin-film-composite hollow-fiber membrane can have an internal burst pressure of at least 4 MPa. In a method for forming the membrane, the polymer concentration in the spinning dope from which the hollow-fiber substrate is formed can have a polymer concentration no greater than 5% below the critical concentration.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
A recombinant cell of Saccharomyces cerevisiae that includes in its genome nucleic acids encoding cannabinoid biosynthetic pathway genes. A cannabinoid is produced by the recombinant cell in the presence of a cannabinoid precursor substrate and at least one of the cannabinoid biosynthetic pathway genes is from an organism other than Cannabis sativa, wherein the at least one of the cannabinoid biosynthetic pathway genes encodes a prenyltransferase. In an embodiment, the prenyltransferase is NphB from Streptomyces sp. having the amino acid sequence of any one of SEQ ID NOs: 8-11. Also disclosed is a method for producing a cannabinoid with the recombinant cell and the cannabinoid precursor substrate.
The present invention concerns the cosmetic field, and especially cosmetic uses of at least one short chain fatty acid chosen from propionic acid, butyric acid, valeric acid, non-metallic salts thereof, esters thereof and mixtures thereof, or a conditioned culture medium obtained from at least one microorganism which is able to produce such short chain fatty acid(s), as antidandruff agent, for preventing and/or treating desquamative disorders of the skin associated with the excessive proliferation of yeasts of the Malassezia genus on the skin and for maintaining and/or restoring at a normal level, the ecoflora of the skin and especially by preventing excessive colonization of the skin by Malassezia genus and/or by mediating growth of Cutibacterium acnes.
A61Q 17/00 - Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
A method for producing a cannabinoid precursor by contacting a substrate and geranyl pyrophosphate or farnesyl pyrophosphate with an NphB orthologue. The NphB orthologue is from an organism other than Cannabis sativa, and the substrate can be 2,4-dihydroxy-6-pentylbenzoic acid or 2,4-dihydroxy-6-propylbenzoic acid. Also disclosed is a recombinant cell of Yarrowia lipolytica, carrying in its genome a nucleic acid encoding an NphB orthologue from an organism other than Cannabis sativa such that the NphB orthologue is expressed in the recombinant cell.
The present invention relates to a process for the separation of propylene from a gas mixture (GM) comprising propylene and propane by means of a membrane (M) comprising a polyarylene ether sulfone polymer (P) prepared by converting a reaction mixture (RG) comprising at least one aromatic dihalogen sulfone and at least one dihydroxy component comprising trimethylhydroquinone.
The present disclosure provides methods and devices for separation of motile sperm. A method of separating motile sperm comprises: introducing a fluid sample comprising motile sperm to an inlet portion of a microfluidic device; and causing the fluid sample to flow through a separation portion of the microfluidic device at a flow velocity within a rheotaxis range such that motile sperm in the sample undergo rheotaxis and remain in the separation whereas a part of the fluid sample flows out of the separation zone through an outlet portion of the microfluidic device.
A method for producing a cannabinoid by contacting cannabigerolic acid with a cannabinoid synthase orthologue. The cannabinoid synthase orthologue is from an organism other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris that includes in its genome a nucleic acid encoding the above cannabinoid synthase orthologue. The cannabinoid synthase orthologue is expressed in the recombinant cell in an active form.
The invention concerns a trans-splicing RNA (tsRNA) molecule comprising one or multiple unstructured binding domains; a cell or vector comprising said tsRNA; and a method for killing cells or treating a disease using said tsRNA.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Embedded memory structures and methods where an array of bitcells is interconnected by a plurality of bitlines and wordlines, each bitcell comprising a transistor connected to one of the wordlines and one of the bitlines. A TRNG circuit, peripheral to the array of bitcells, sets transistors connected to the one or more of the bitlines to an off state, determines a time interval between different crossing thresholds in a voltage discharge in the bitlines, and digitizes the time interval into bits of an TRNG output. A PUF circuit. peripheral to the array of bitcells, sets a pair of transistors connected to the pair of bitlines and the same wordline to an underdriven state, determines respective times of the transistors of the pair crossing a threshold in a voltage discharge in the pair of bitlines, and digitizes a time difference into an n-bit PUF output.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
16.
SURFACE TREATMENT METHOD FOR FORMING A PASSIVATED CONTACT OF A SOLAR CELL
Surface treatment method for forming a passivated contact of a solar cell A surface treatment method for forming a passivated contact of a solar cell 100 is described. In an embodiment, the solar cell 100 comprises a silicon layer 102 having a textured surface, and the method comprises: (i) etching a portion of the silicon layer 102 using a first etchant to reduce surface protrusions of the textured surface and to provide an intermediate surface of the silicon layer 102; and (ii) etching the intermediate surface of the silicon layer 102 using a second etchant to form a treated surface of the silicon layer 102 having a desired roughness for forming the passivated contact of the solar cell, the second etchant having a slower etching rate on silicon than that of the first etchant.
The present disclosure generally relates to a robotic gripper comprising: a body; a plurality of displacement mechanisms; a plurality of finger modules removably connected or connectable to the body, such that each finger module engages with a respective displacement mechanism; each finger module comprising a finger actuator cooperative with the other finger actuators for gripping an object; and each displacement mechanism is configured for moving the respective finger module to adjust its arrangement on the body, thereby configuring the robotic gripper for gripping the object.
The invention relates to an artificial antigen-presenting cell (aAPC) comprising at least one immune stimulatory ligand and co-stimulatory ligands comprising or consisting of CD86, CD70 and CD137L, methods of preparing an aAPC and methods of inducing proliferation of an immune cell or expanding a population of immune cells. The invention also relates to methods for inducing an immune response or treating a medical condition in a subject. The invention further relates to methods of identifying an antigenic peptide or method of identifying or detecting the presence of an immune cell that recognizes an antigen.
Disclosed herein are methods of bioproduction of enantiomerically pure or enantiomerically enriched 2-phenylglycinol or a derivative thereof by multiple enzyme-catalyzed chemical transformations in a one-pot reaction system.
The present invention relates to nucleic acids, double stranded nucleic acids (dsNAs), and agents for inhibiting expression of STATS. The present invention also includes nanoparticles comprising the nucleic acids, the dsNAs, and/or the agents as well as methods of treating cancer using the nucleic acids, the double stranded nucleic acids (dsNAs), the agents and/or the nanoparticles as disclosed herein. In one embodiment, the target region is within the 3′-UTR region of STATS mRNA.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to a composite membrane comprising at least one 2D material and an inorganic porous material. The composite membrane described herein may be housed within a separation device which may be used for selective permeation of one or more gaseous compounds.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
A protective article is described. The protective article comprises auxetic structures including: (i) a first auxetic structure having a first auxetic plane exhibiting auxetic behaviour and a first auxetic structure axis, the first auxetic structure axis being substantially perpendicular to the first auxetic plane; and (ii) a second auxetic structure having a second auxetic plane exhibiting auxetic behaviour and a second auxetic structure axis, the second auxetic structure axis being substantially perpendicular to the second auxetic plane. The second auxetic structure axis is arranged in a non-parallel relationship to the first auxetic structure axis. An auxetic structure for use in a protective article and a method for forming the auxetic structure are also described.
The present invention relates to the detection of target nucleic acids using enzyme-assisted nanotechnology. More specifically, the present invention provides a molecular nanotechnology in the form of a transition-state DNA-enzyme molecular switch and methods of use that enables direct and sensitive detection of viral RNA targets in native clinical samples. In one embodiment, the detection comprising steps of providing a composition comprising at least one DNA polymerase enzyme, at least one enhancer, and at least one DNA polymerase inhibitor, wherein the DNA polymerase inhibitor is recognized and bound by the DNA polymerase enzyme via its conserved region, and is complementary to a portion of the enhance via its variable region. In another embodiment, the detection method comprising steps of providing a signalling nanostructure and detecting signal development, wherein a change in the intensity of signal. In an alternative embodiment, the target nucleic acid is a SARS-CoV-2 polynucleotide.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
24.
A HIGHLY SENSITIVE HEAT-REPRESSIBLE SPLIT-T7 POLYMERASE (THERMAL-T7RNAP) FOR APPLICATIONS IN BIOTECHNOLOGY
The present invention relates to heat-repressible split-T7 polymerases comprising temperature-sensitive domains of Tlpa protein fused with split T7 RNA polymerase (T7RNAP) to introduce thermal control into widely used T7 RNA polymerase, creating a heat-repressible Thermal-T7RNAP system. The invention further provides polynucleotides encoding the heat-repressible split-T7 polymerases, and methods of thermal control of bioproduction.
Disclosed herein is a nanomaterial electrolyte formed from a modified two-dimensional nanomaterial having a surface, where the surface is modified by a plurality of functional groups selected from one or more of the group consisting of imine, sulfonic acid, sulfonamide, amine, hydroxyl, carboxylic acid, thiol, and amide on the surface of the modified two-dimensional nanomaterial, where the nanomaterial electrolyte is capable of reversibly adopting a flat two-dimensional conformation or a scrolled 1-dimensional conformation upon a change to its ambient environment. There is also disclosed a method of effecting a change in conformation from one form to the other (and back again).
A memory device for deep neural network, DNN, accelerators, a method of fabricating a memory device for deep neural network, DNN, accelerators, a method of convoluting a kernel [A] with an input feature map [B] in a memory device for a deep neural network, DNN, accelerator, a memory device for a deep neural network, DNN, accelerator, and a deep neural network, DNN, accelerator. The method of fabricating a memory device for deep neural network, DNN, accelerators comprises the steps of forming a first electrode layer comprising a plurality of bit-lines; forming a second electrode layer comprising a plurality of word-lines; and forming an array of memory elements disposed at respective cross-points between the plurality of word-lines and the plurality of bit-lines; wherein at least a portion of the bit-lines are staggered such that a location of a first cross-point between the bit-line and a first word-line is displaced along a direction of the word-lines compared to the cross-point between said bit-line and a second word-line adjacent the first word-line; or wherein at least a portion of the word-lines are staggered such that a location of a cross-point between the word-line and a first bit-line is displaced along a direction of the bit-lines compared to a cross-point between said word-line and a second bit-line adjacent the first bit-line.
A method of clock synchronization between first and second clocks on first and second ends, respectively, of an optical channel; and a system for clock synchronization between first and second clocks on first and second ends, respectively, of an optical channel. The method comprises the steps of generating light exhibiting thermal photon statistics, as opposed to a Poissonian timing statistic of coherent laser light; transmitting a portion of the light though the optical channel; determining timing information of single photon detection events of photons of the light at the first side of the optical channel using the first clock and at the second side of the optical channel using the second clock; using a temporal signature imprinted on the light as a result of the thermal photon statistics to identify temporal correlations between the single photon detection events at the first side of the optical channel and the single photon detection events at the second side of the optical channel; and determining an offset between the first and second clocks based on the identified temporal correlations.
An apparatus for collecting a saliva sample is described herein. In a described embodiment, the apparatus comprises a filter; and a pressure generator operable to generate pressure to cause the saliva sample to be transferred through the filter, the filter being configured to reduce a viscosity of the saliva sample as the saliva sample is transferred through the filter. A method collecting a saliva sample from a user is also described, among other aspects.
A method and a system for training a neural network. The method includes receiving, by a processing device, a training image, a reference label and a reference class activation map, the reference label and the reference class activation map associated with a corresponding unbiased image of the training image and generating, using the processing device, a class label and a class activation map based on the training image using the neural network. The method also includes calculating, using the processing device, a classification loss value based on differences between the reference label and the class label, and a class activation map loss value based on differences between the reference class activation map and the class activation map and updating, using the processing device, the neural network to minimise the classification loss value and the class activation map loss value to improve accuracy of the neural network in generation of the class label and the class activation map.
A method of fabricating low dimensional nanostructures on a growth substrate, a single-crystalline low dimensional nanostructure, and a device comprising one or more single-crystalline low dimensional nanostructures. The method comprises fabricating low dimensional nanostructures on a growth substrate using physical vapor deposition, PVD, in a vacuum chamber wherein the low dimensional nanostructures are formed as a strain relief mechanism promoted by a similarity of crystal structure 2-dimensional symmetry between the growth substrate and the low dimensional nanostructures to be grown and a lattice mismatch between the growth substrate and the low dimensional nanostructures to be grown.
An ion microscope, a method of constructing an ion microscope, and a method of aligning an ion beam in an ion microscope. The microscope comprises a nano-aperture ion source; and a focusing system; wherein the focusing system is configured for selectively coaxially focusing an ion beam generated from an electron beam ionizing an ionizing gas in the nano-aperture ion source and the electron beam.
NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
PAXMAN COOLERS LTD (United Kingdom)
Inventor
Sundar, Raghav
Bandla, Aishwarya
Paxman, Neil
Paxman, Glenn
Moses, Rodney
Abstract
A compression apparatus for applying pressure to a subject is provided. The compression apparatus comprises a compression system; and one or more compression components connected to the compression system and secured around the subject, the one or more compression components comprising an air cavity. A method of applying pressure to a subject is also provided.
The present invention relates to a digital CRISPR-based method for detecting and quantitating target nucleic acids in a sample comprising: forming a mixture comprising sample nucleic acids; isothermal amplification reaction reagents for amplifying one or more target nucleic acid sequences; partitioning the mixture into a plurality of compartments; incubating the partitioned mixture at a temperature for isothermal amplification and Cas effector cleavage of an amplified DNA strand, detecting a signal from cleavage of the non-target sequence, thereby detecting the one or more target sequences in the sample, and determining the copy number of the target nucleic acid based on a Poisson distribution of the proportion of positive-to-negative compartments. The invention also relates to a method for detecting presence and/or of a disease in a subject, and a kit to quantitate nucleic acids in a sample.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
PAXMAN COOLERS LTD. (United Kingdom)
Inventor
Sundar, Raghav
Bandla, Alsharya
Binder, Jonathan Rex
Burke, Patrick
Unver, Ertu
Abstract
A compression wrap and method for temperature-controlled application of pressure on an arm of a subject, comprising a fluid bladder comprising a first element comprising two or more first flaps; a second element comprising one or more digital flaps; and a third element comprising two or more second flaps, wherein the first element and the third element are connected along a first edge and the second element is connected to the first element and the third element along a second edge.
The present disclosure teaches a method of predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy. In one embodiment, there is provided a method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
A system to provide a human-machine interface to enable a user in a real space to act/sense in a virtual space. The system includes: a ring wearable by a finger of the user; a plurality of sensors, and a plurality of feedback units. The plurality of sensors being multimodal, including: a tactile sensor disposed on an inner surface of the ring; and a temperature sensor disposed on an outer surface of the ring. The plurality of feedback units being multimodal, including: a vibrator disposed on the ring, the vibrator being disposed on the outer surface of the ring; and a heater disposed on the inner surface of the ring. The system includes a controller configured to drive the plurality of sensors and the plurality of feedback devices to enable concurrent multimodal sensing and multimodal feedback.
Disclosed herein is a spatially decoupled redox flow water electrolyzer, that has a hydrogen-producing catholyte section formed from a catholyte tank, having a cathode, and a hydrogen generation compartment, where the catholyte tank and the hydrogen generation compartment are fluidly connected to one another by a fluid pathway, so as to facilitate the circulation of a liquid catholyte from the catholyte tank to the hydrogen generation compartment and back to the catholyte tank and an oxygen-producing anolyte section formed from an anolyte tank, having an anode, and an oxygen producing compartment, where the anolyte tank and the oxygen producing compartment are fluidly connected to one another by a fluid pathway, so as to facilitate the circulation of a liquid anolyte from the anolyte tank to the oxygen producing compartment and back to the anolyte tank, an anion-exchange membrane is disposed between the catholyte and anolyte tanks and a current collector attached to the catholyte and anolyte tanks. In use, the hydrogen generation compartment contains a catalyst capable of catalysing hydrogen production when brought into contact with a cathodic redox mediator when the cathodic redox mediator is in a reduced state and the oxygen generation compartment contains a catalyst capable of catalysing oxygen production when brought into contact with an anodic redox mediator when the anodic redox mediator is in an oxidised state.
Agency for Science, Technology and Research (Singapore)
Inventor
Khin, Phone May
Low, Jin Huat
Chen, Chao-Yu
Yeow, Chen Hua
Zhang, Ying
Abstract
A gripping device comprising: a base; at least one pair of extendable linkages connected at a proximal end to the base; each extendable linkage having a gripping finger extending from a distal end of the extendable linkage; wherein the extendable linkages are arranged to extend or retract from the base so as to increase a radial distance between the gripping fingers.
The present disclosure relates to the diagnosis, treatment and prophylaxis of age-related diseases, and increasing healthspan. Provided are methods of treating or preventing an age-related disease/condition, and in particular of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject. Also provided are agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in such a method. Further provided is the use of agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in such a method.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 43/00 - Drugs for specific purposes, not provided for in groups
There is provided a multi-layered sheet mask comprising at least (a) a porous first layer having a first side and a second side, wherein the first side is opposite to the second side, and comprises a plurality of three-dimensional patterns extending therefrom; (b) a second layer attached to the second side of the porous first layer, the second layer comprising at least one pouch for receiving or containing at least one first active ingredient; a porous support structure; an air pouch that is sandwiched between the second side of the porous first layer and the porous support structure; and a plurality of microchannels that extend from the pouch and beyond the first side of the porous first layer when the air pouch is deflated; and (c) a third layer attached to the second layer for receiving or containing at least one second active ingredient. There is also provided a mould for producing the three-dimensional patterns of the porous first layer of the multi-layered sheet mask, and a method of producing the multi-layered sheet mask.
The present invention relates to a composition comprising or consisting of two or more bacteria strains, formulated for the prophylaxis or treatment of intestinal barrier dysfunction and/or heat stress in a subject. More particularly, the composition comprises two or more of Lactobacillus reuteri MM2-3, Lactobacillus plantarum WCSF1, Streptococcus thermophilus B of R and Escherichia coli Nissle 1917. The present invention also includes uses of the invention to treat conditions such as inflammatory bowel disease (IBD) and heat stress.
The present disclosure relates to a method of 3D printing a stent, comprising performing selective laser melting on a Nitinol powder in order to form the stent, wherein selective laser melting is performed with particular parameters. The 3D printed stent can be curved. The present disclosure also relates to the 3D printed stent thereof, a stent delivery device comprising a tube and a crimped 3D printed stent slidably disposed within the tube, and a method of delivering a stent in a stent delivery device into a channel.
A61F 2/915 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
A61F 2/966 - Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
B22F 5/10 - Manufacture of workpieces or articles from metallic powder characterised by the special shape of the product of articles with cavities or holes, not otherwise provided for in the preceding subgroups
B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
B22F 10/366 - Scanning parameters, e.g. hatch distance or scanning strategy
B22F 10/368 - Temperature or temperature gradient, e.g. temperature of the melt pool
43.
A METHOD TO MONITOR VIRUS-SPECIFIC T CELLS IN BIOLOGICAL SAMPLES
The present invention relates to a method of diagnosing and/or monitoring of virus infection and/or response to vaccination by generating a profile of a virus-specific T cell response that can (i) discriminate between virus infected and uninfected individuals, (ii) determine the effect of vaccination on T cell response, and (iii) determine the effect of viral variants on T cell response. More particularly, the described virus-specific T cell profiling is based on the detection of activated antigen-specific T lymphocytes responding to pools of selected short peptides from virus proteins. These peptide sequences have been selected for their immunogenicity. The profiling is typically performed using ELISPOT, but may also be performed using other techniques such as qPCR, more particularly direct qPCR. The present invention also includes kits for use in the methods of the invention.
Agency for Science, Technology and Research (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Chin, Zheng Yang
Zhang, Haihong
Guan, Cuntai
Wang, Chuan Chu
Lee, Tih Shih
Abstract
Disclosed is a system for sensor-based training intervention. The system includes one or more electroencephalogram (EEG) sensors for retrieving brain signals of a subject, one or more sensors for retrieving eye tracking data of one or both eyes of the subject, and one or more processors. The one or more processors are configured to model a joint state space of the brain signals and eye tacking data by combining the brain signals and eye tracking data into combined data using sequential Bayesian fusion, and measure a visuospatial attention indicator from combined data.
An optical range finding device and an optical range finding method. The method comprises the steps of generating light with a super Poissonian timing statistic; splitting the light into a reference beam and a probe beam and directing the probe beam towards a target in free-space; illuminating a first single-photon detector by the reference beam; illuminating a second single-photon detector by the probe beam after reflection by the target in free-space; detecting a time difference between detection of quantum-correlated photons in the reference beam and the reflected probe beam for determining a distance between the device and the target.
The invention relates generally to cell-derived vesicles (CDVs), such as CD Vs from myoblast, wherein the parent cells have been subjected to pulsed electromagnetic field and wherein the vesicles are isolated from the parent cells using actin cytoskeletal disruptors, such as cytochalasin B. The CDVs are enriched for Transient Receptor Potential Channel 1 (TRPC1). The invention further relates to the uses of the CDVs as therapeutic agents in conditions associated with disruptive metabolism and inflammation; for instance, cancer.
NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD (Singapore)
Inventor
Kofidis, Theodoros
Abstract
A retractor-camera kit for minimally invasive surgery is provided. The kit includes a retractor comprising at least a top blade and a first side blade connected to one another through a hinge, a handle connected to the retractor, and a camera connected to the retractor via a designated holder to provide visualization of a surgical site while avoiding the need for an additional incision for passing an imaging unit therethrough.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 17/02 - Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
A method of optimising one or more physical properties of an alloy comprises conducting a plurality of trials per an experimental design on a plurality of candidate alloys. Each trial comprises measuring a plurality of values of each physical property of the candidate alloys for different values of a plurality of parameters, wherein the parameters comprise respective concentrations of the two or more constituents, and one or more process parameters. The method further comprises fitting the plurality of values of the physical property and the plurality of parameters to a response surface model; and determining, from the fitted response surface model, optimised values of the parameters that optimise the respective responses; wherein the response surface model describes a non-linear relationship between a time integral of each of the physical property and a linear combination of non-linear functions of the plurality of parameters.
C22C 23/02 - Alloys based on magnesium with aluminium as the next major constituent
C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
B22D 21/00 - Casting non-ferrous metals or metallic compounds so far as their metallurgical properties are of importance for the casting procedure; Selection of compositions therefor
49.
METHOD AND SYSTEM FOR RECORDING AN IMAGE USING ONE OR MORE PRISMS
A method and system for recording an image using a camera. The method comprises the steps of: disposing a first reflective prism in front of the camera such that the first prism deflects light from a first field of view onto a sensor of the camera, wherein the first field of view extends symmetrically around a non-perpendicular direction relative to an entrance lens surface of the camera; capturing a first image over at least a portion of the first field of view using the sensor; and capturing a second image over at least a portion of a second field of view different from the first field of view using the same sensor with the first prism in place in front of the camera.
The present invention generally provides, in various embodiments, methods of generating tagged DNA amplicons for sequencing. In one embodiment, the method comprises a) annealing a first oligonucleotide to a nucleic acid template comprising a target nucleic acid molecule sequence and a tag sequence, wherein the target nucleic acid molecule sequence comprises a locus of interest; b) performing nucleic acid template-directed nucleic acid extension from the annealed first oligonucleotide to provide a first extension product; c) circularizing the first extension product to produce a circularized DNA template; and d) performing circularized DNA template-directed nucleic acid amplification to produce a tagged DNA amplicon for sequencing. The methods are useful for linking a distant locus-of-interest to a reverse transcription primer.
The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCRαβ-deficient T cells and CD3/TCRαβ-deficient chimeric antigen receptor T cells that express such PEBLs.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
C12N 15/62 - DNA sequences coding for fusion proteins
52.
Influenza vaccine, composition, and methods of use
Institut National de la Sante et de la Recherche Medicale (INSERM) (France)
National University of Singapore (Singapore)
Inventor
Alonso, Sylvie Claudette
Li, Rui
Chow, Vincent Tk
Locht, Camille
Abstract
The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
The present invention relates to catalytic, nucleic acid nanostmctures that enable versatile detection of RNAs, their use, and devices comprising same. The nanostructure comprises a DNA polymerase enzyme, a DNA aptamer and an inverter oligonucleotide, wherein the DNA aptamer comprising (i) a conserved sequence region for binding to the DNA polymerase enzyme, wherein the binding inactivates the polymerase activity, (ii) a variable sequence region for binding to the inverter oligonucleotide, and (iii) a duplex stabilizer region that lies between the conserved sequence region and the variable sequence region. The present invention also relates to the use of the nanostructure in a method of detection of nucleic acid for diagnosing a disease in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a method and system for identifying and validating pairs of candidate antigens and their cognate antigen-specific T lymphocytes that are useful for validating the immunogenic activity of paired antigen and TCR sequences. The method includes, inter alia, steps of determining one or more splice variants that are more highly transcribed in a sample obtained e from cohort of patients compared to a reference sample, determining one or more amino acid sequences that occur in an amino acid translation of said one or more splice variants but not in the corresponding splice variant in the reference sample, and predicting HLA binding of the amino acid sequences in order to identify candidate shared antigen. The present invention also relates to methods of characterising and/or treating a medical condition, including cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
55.
IMMUNOSUPPRESSANT DRUG RESISTANT ARMORED TCR T CELLS FOR IMMUNE-THERAPY OF ORGAN TRANSPLANT PATIENTS
Described are novel immunosuppressant drug resistant armored (IDRA) T cells that co-express an exogenous T cell receptor (TCR) and one or more exogenous inhibitors of an immunosuppressant. The TCR can bind to an antigen expressed by a tumor cell or virally infected cell. Also described are methods of producing the modified T cell, and methods of treating a subject using the modified T cells.
A classifying sensing system, a classifying method performed using a sensing system, a tactile sensor, and a method of fabricating a tactile sensor. The classifying sensing system comprises a first spiking neural network, SNN, encoder configured for encoding an event-based output of a vision sensor into individual vision modality spiking representations with a first output size; a second SNN encoder configured for encoding an event-based output of a tactile sensor into individual tactile modality spiking representations with a second output size; a combination layer configured for merging the vision modality spiking representations and the tactile modality spiking representations; and a task SNN configured to receive the merged vision modality spiking representations and tactile modality spiking representations and output vision-tactile modality spiking representations with a third output size for classification.
The present invention relates, in general terms, to X-ray detecting films and uses thereof. The present invention also relates to methods of fabricating the X-ray detecting films. In particular, the X-ray detecting film comprises persistent luminescent nanoparticles dispersed within a flexible polymer matrix, wherein the persistent luminescent nanoparticles are dispersed in the flexible polymer matrix at a concentration of about 0.1% to about 100%.
A method of generating true random numbers for use by a cryptographic hardware component for cryptographic algorithms or communication protocols, and a cryptographic hardware component for cryptographic algorithms or communication protocols. The method comprises the steps of controlling a clock pulsewidth, PW, for pulsed-latch clocking in the cryptographic hardware component to switch between using the cryptographic hardware component to generate the true random numbers in a first operating state; and using the cryptographic hardware component for cryptographic processing in a second operating state.
Disclosed herein are vapour-phase crosslin ked composite membranes in the form of crosslinked polymers and defined inorganic materials. The membranes disclosed herein may have a narrow pore size distribution and precise molecule separation ability and may be used for organic solvent nanofiltration and organic solvent reverse osmosis. Also disclosed herein are methods of forming the membranes, and filtration. In a preferred embodiment, the vapour-phase crosslinked composite membrane is obtained by exposing a composite membrane comprising polyimide and UiO-66-NH2 particles to an amine vapour.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
The present invention relates, in general terms, to a method of extracting resin glycoside from a plant selected from the Convolvulaceae family. The resin glycosides can be extracted from Ipomoea batatas and/or Ipomoea aquatica. The present invention also relates to the extracts and edible compositions thereof and its use in weight loss and weight management.
A61K 36/39 - Convolvulaceae (Morning-glory family), e.g. bindweed
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
The present invention relates to a method for producing a bacterial microcompartment virus-like particle (VLP) carrying a cargo molecule, the method comprising introducing and expressing in a host cell or organism one or more polynucleotides comprising (a) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding a cargo molecule fused to an encapsulation peptide comprising the sequence SKITGSSGNDTQGSLITYSGGARG, and forming a microcompartment that encapsulates the cargo molecule, or (b) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding at least one of said protomers fused with a cargo molecule or a biochemical tag, and forming a microcompartment that expresses the cargo molecule or biochemical tag on an exterior surface. In one embodiment, the bacterial microcompartment protomers are CsoSIA and CsoS4A from Halothiobacillus neapolitanus, or HO-H, HO-P and HO-T1 from Haliangium ochraceum.
The present invention relates to a method of preparing a three-dimensional (3D) cell composition comprising the steps of a) forming a support matrix containing oral fibroblasts suspended within the support matrix by mixing fibrinogen, a modifier and oral fibroblasts with thrombin, b) incubating the support matrix in a cell culture media for a sufficient time to allow development of a first layer of the three-dimensional cell composition, and c) seeding oral keratinocytes on a surface of the first layer and culturing the oral keratinocytes to form a second layer of the three-dimensional cell composition. In specific embodiments of the invention, the method is exemplified for the production of an artificial gingival tissue, wherein polyethylene oxide), 4-arm, succinimidyl glutarate terminated is used as the modifier. Also disclosed are uses of the 3D cell composition which include treatment of a gum disease or condition, regenerative therapy and for in vitro testing.
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
The present disclosure relates to methods for culturing human epidermal keratinocytes. When keratinocytes are cultured on plates coated with a laminin containing an alpha-4 chain or an alpha-5 chain, in a xeno-free, chemically defined cell culture medium, they expand efficiently in vitro. Useful cell culture kits for culturing keratinocytes are also described herein, as are methods of using such cells for treatment of burns or chronic wounds.
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
66.
ASSEMBLY AND METHOD FOR SWITCHING DIRECTION OF CAMERA VIEW
An assembly and method of switching direction of camera view. The method comprises disposing a beam splitter element on a camera, the beam splitter element being configured such that first and second beams of light incident on first and second faces, respectively, of the beam splitter element are directable towards an entry lens of the camera; disposing first and second shutter elements in the paths of the first and second beams of light, respectively; and controlling the first and second shutter elements such that one of the first and second shutter elements is in an open state while the other one is in a closed state, and vice-versa.
Tyco Electronics Holdings (Bermuda) VII Ltd (Taiwan, Province of China)
Tyco Electronics Singapore Pte Ltd (Singapore)
National University of Singapore (Singapore)
Inventor
Cheah, Sin-Hooi
Wong, Kim Hai
Liu, Wei
Chen, Zhining
Abstract
An antenna assembly includes a metasurface antenna unit including a radiating structure, a feeding structure, and a grounding structure therebetween. The radiating structure includes radiating elements arranged in an m×n grid of m rows of radiating elements and n columns of radiating elements, where n is greater than m. The radiating elements are separated by radiating slots with edges of the radiating elements facing each other across the radiating slots. The grounding structure includes a ground plane having a coupling aperture therethrough. The feeding structure includes a single strip feedline for feeding the radiating elements. The strip feedline passes across the coupling aperture and feeds the radiating structure through the coupling aperture. At least one of the radiating elements is fed through at least one other radiating element across the corresponding radiating slot.
Apparatuses and methods for forming a film on a substrate are described. The film is formed on the substrate by depositing an adamantane monomer and an initiator on the substrate to form a polymerizable seed layer and curing the polymerizable seed layer to form a polyadamantane layer.
C08F 2/48 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 16/511 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating using electric discharges using microwave discharges
C23C 16/02 - Pretreatment of the material to be coated
69.
MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS
The present disclosure describes a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus β2.7 RNA, wherein each subdomain is capable of localization within the mitochondria, for transport into mitochondria. Disclosed herein are also methods of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both, as well as methods of treating a mitochondrial disorder.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A heat transfer device includes at least one channel including an upstream zone, a downstream zone, and a mixing zone intermediate the upstream and downstream zones. The upstream zone includes an upstream separating configuration arranged to separate an inflow to the upstream zone into a plurality of upstream sub-flows. The mixing zone includes a converging configuration arranged to converge at least two upstream sub-flows into the mixing zone to form a primary mixed flow.
F28F 13/12 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by affecting the pattern of flow of the heat-exchange media by creating turbulence, e.g. by stirring, by increasing the force of circulation
F28F 1/12 - Tubular elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with projections, with recesses the means being only outside the tubular element
The present disclosure relates to a method of colony picking. The method includes the steps of mixing a bacterial suspension with an oil-based carrier liquid for generating a plurality of droplets comprising bacteria contained in the bacterial suspension and incubating the plurality of droplets for a predetermined period of time to allow growth of bacteria within the plurality of droplets. The method further includes the steps of screening each of the plurality of droplets that flows through one or more microfluidic channels of a microfluidic device to determine an opacity degree of each of the plurality of droplets, wherein the opacity degree is indicative of colony formation in the plurality of droplets, and sorting the plurality of droplets based on the opacity degree of each of the plurality of droplets.
The present invention relates to miRNA interference technology. More specifically the invention relates to circular miRNA sponges that carry a plurality of binding sites directed to at least two types of miRNA and separated by random, non-identical spacers, allowing for the inhibition of functional classes of m1RNAs. Preferably, the binding sites are bulged binding sites wherein each bulge is created by a one base deletion and two base mismatch at positions 9-11 nt from the 3′ end of each binding site. Preferably, each spacer is 6 to 24 nucleotides in length. Preferably, the binding sites are against miR-132 and miR-212, miR-17-5p and miR-18a-5p, or miR-20b-5p and miR-106a-5p. Construction vectors and uses of said miRNA sponges for the treatment of diseases, such as cardiomyopathy and cancer, are also disclosed.
The present invention provides a system for eliminating microorganisms comprising a plurality of light emitters, wherein each of the plurality of light emitters is configured to emit light comprising a wavelength of 380-500 nm, and wherein at least two or more of the plurality of light emitters emit light of a different wavelength. There is also provided a method of eliminating microorganisms comprising emitting a light of a wavelength of 380-500 nm by each of a plurality of light emitters.
Disclosed is an apparatus for collecting part of an exhaled breath. The apparatus comprises a chamber comprising an internal surface defining a sample collection volume that has been functionalised to not interact chemically or physically with volatile components in the breath, an inlet end and outlet end through which the breath respectively enters and exits the sample collection volume. The apparatus also includes two closures, one at each of the inlet end and the outlet end to control passage of the breath through the respective inlet end or outlet end, the closures being actuated to capture the part of the exhaled breath, and a sampling port accessible from outside the chamber and in communication with the sample collection volume. The chamber is further tapered in its diameter toward each of the inlet end and outlet end to maintain laminar flow through the chamber.
An optical power limiter, a method of fabricating the optical power limiter, a method of limiting optical power, a method of upper bounding information leakage in quantum cryptography, and a quantum cryptography system. The optical power limiter comprises an optical input port; an optical output port; an effective medium disposed between the input port and the output port; and a diaphragm disposed between the effective medium and the output port; wherein the effective medium has a thermo-optic coefficient such that a light beam entering the effective medium from the direction of the input port experiences a refractive index gradient in a direction perpendicular to a propagation direction in the effective medium as a result of absorption; and wherein the diaphragm is disposed in a path of the light beam for limiting how much of the light beam reaches the output port.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
H04B 10/291 - Repeaters in which processing or amplification is carried out without conversion of the main signal from optical form
A method of encoding quantum information on one or several degrees of freedom of coherent states of photons of a baseband input optical signal, a quantum transmitter, and a computer-readable medium. The quantum transmitter comprises a modulator configured to encode quantum information on one or several degrees of freedom of coherent states of photons of a baseband input optical signal using sideband modulation of the baseband optical input signal.
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
SINGAPORE HEALTH SERVICES PTE. LTD. (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Sabapathy, Tr Kanaga
Lane, David P.
Hwang, Le-Ann
Koh, Xin Yu
Wah, Liew Oi
Abstract
The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using as an immunogen a peptide or polypeptide comprising: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration. Also provided are antibodies produced by such methods, and uses thereof.
Hard masks and methods of forming hard masks are described. The hard mask has an average roughness less than 10 nm and a modulus greater than or equal to 400 GPa. The method comprises exposing a substrate to a deposition gas comprising a dopant gas or a precursor (solid (e.g. Alkylborane compounds) or liquid (e.g. Borazine)), a carbon gas and argon at a temperature less than or equal to 550 C, and igniting a plasma from the deposition gas to form an ultrananocrystalline diamond film having an average roughness less than 10 nm and a modulus greater than or equal to 400 GPa.
The present invention relates to treatment of coronavirus-induced disease, specifically COVID-19 disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary and/or vascular pathologies. The treatment comprises administering to a subject a composition comprising a mast cell stabilizer and/or inhibitor of mast cell products, such as TY-51469, nafamostat mesylate, cromolyn, or ketotifen. The invention also provides a method of diagnosing a subject as having SARS-CoV-2, the method comprising determining the level and/or activity of a mast cell protease such as chymase or tryptase in the serum from a subject.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
PEPTIDE ADJUVANT FOR ITS THERAPEUTIC APPLICATIONS IN VIRAL AND TUMOUR VACCINE DEVELOPMENT AND CANCER IMMUNOTHERAPY AND AUTOIMMUNE DISEASE DIAGNOSIS AND TREATMENTS
The present invention relates to an isolated peptide, comprising or consisting of a glycine and arginine-rich (GAR/RGG) region with alarmin and/or cell penetrating activity, bioactive fragments or mutants thereof, and compositions comprising the peptide and an antigen or cargo molecule for vaccine development, immunotherapy, and/or the delivery of nucleic acids and proteins into cells. Further, the invention provides a method of detection using these peptides, and a process of producing the peptides.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
81.
CHALCOGEN PRECURSORS FOR DEPOSITION OF SILICON NITRIDE
Chalcogen silane precursors are described. Methods for depositing a silicon nitride (SixNy) film on a substrate are described. The substrate is exposed to the chalcogen silane and a reactant to deposit the silicon nitride (SixNy) film. The exposures can be sequential or simultaneous. The chalcogen silane may be substantially free of halogen. The chalcogen may be selected from the group consisting of sulfur (S), selenium (Se), and tellurium (Te).
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
C23C 16/44 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
82.
METHOD AND SYSTEM FOR MEASUREMENT-DEVICE-INDEPENDENT QUANTUM KEY DISTRIBUTION NETWORK
A measurement-device-independent (MDI) quantum key distribution (QKD) network, a method of operating an MDI QKD network comprising a common server and a plurality of user systems, a user system for a MDI QKD network, and a method of operating a user system for a MDI QKD network. The method of operating an MDI QKD network comprising a common server and a plurality of user systems comprises the steps of performing optical pulse generation and distribution using a laser source at the common server; receiving the optical pulses at the user systems from the common server; modulating the optical pulses at the user systems for quantum communication; re-transmitting the modulated optical pulses from the user systems to the common server; and using an energy bounding component at each of the user system for limiting Trojan horse attack (THA).
A non-invasive method and system for monitoring core body temperature (Tc) of a user continuously so as to prevent the risk of over-heating. The system comprises a detection unit to be worn in the user's ear for measuring physiological data of the user by a plurality of sensors and an analysis unit connected to the detection unit via a communication link for computing Tc of the user with a prediction model using the physiological data measured by the detection unit where the effects of heart rate and external environmental temperature on auditory canal temperature of the user are taken into account. The sensors comprise two sensors (207, 208) for measuring auditory canal temperatures and sensors (209, 210) for measuring heart rate and external auricle temperature respectively. The prediction model is preferably a random forest prediction model or a linear or polynomial regression model. An over-heating state of the user is determined when the computed Tc is above a threshold level (e.g. above 40° C.).
A microfluidic chip is disclosed herein. In a specific embodiment, the microfluidic chip comprises at least one microfluidic reservoir having a wall portion and a heat transfer sealing layer cooperating with the wall portion for receiving a sample to be tested. The heat transfer sealing layer is arranged to be contiguous with the sample to be tested. The microfluidic chip further comprises an active temperature control device arranged to provide structural support to the heat transfer sealing layer and operable to control a temperature of the sample via transmission of heat through the heat transfer sealing layer. A detection module is also disclosed.
The invention relates to a tea-based beverage comprising probiotics, wherein the probiotics has a live probiotic cell count of ≥6.0 log CFU/ml. The invention further relates to a method of preparing the tea-based beverage having a live probiotic cell count of ≥6.0 log CFU/ml comprising the steps of: mixing tea infusion with sugar to form a mixture, inoculating probiotics to the mixture to form an inoculated mixture, fermenting the inoculated mixture for a pre-determined period of time to form the beverage. In one embodiment, the probiotics comprises Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus ermentum, Lactobacillus rhamnosus, Lactobacillus paracasei, Saccharomyces boulardii, Saccharomyces cerevisiae, or a combination thereof.
Agency for Science, Technology and Research (Singapore)
National University of Singapore (Singapore)
Inventor
Tostado, Christopher Peter
Toh, Yi-Chin
Dasgupta, Ramanuj
Abstract
There is provided a microfluidic device comprising a first region configured to hold target cells, e.g., tumor cells, a second region configured to hold effector cells, e.g., immune cells, and an array of microstructures disposed between the first and second regions, wherein the first region is in fluid communication with the second region, and wherein the array of microstructures is configured to selectively allow movement of immune cells, from the second region to an interaction zone that is at least partially disposed within the first region, for interaction with tumor cells in the interaction zone. The array of microstructures can be an array of micropillars. Also provided is a chip comprising a plurality of the device and a method of studying interactions of a first cell type with a second cell type.
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
The invention relates to methods for detecting and/or characterising a nanovesicle in a sample or a method of detecting a target that is bound or associated with said nanovesicle, wherein the sample is brought into contact with nanoparticles that are capable of binding on the surface of nanovesicle and form, in situ, a nanoshell that surround said nanovesicle. In a preferred embodiment, the nanovesicle is exosome labelled with fluorescent probes and the nanoparticles are gold nanoparticles (AuNP). The invention also relates to a kit or microfluidic chip for performing such methods, as well as a method of determining the prognosis of a cancer in a subject by performing such methods.
The present invention relates to a method of treating lymphedema comprising administering an effective amount of a composition to a patient in need thereof. The composition consisting essentially of cyclodextrin or a pharmaceutically acceptable salt, solvate or prodrug thereof. The present invention also relates to a composition consisting essentially of cyclodextrin.
Disclosed herein is a method of detecting the presence of a target analyte in a sample. Disclosed herein are also a system, an article, and a kit for detecting the presence of a target analyte in a sample. Disclosed herein is also the use of the system, or the article, or the kit for biomolecule, bioorganelle, bioparticle, cell and microorganism detection.
The current invention relates to the use of a neural network to improve the quality of images obtained from light scattered by an intermediate object that scatters light, such as tissue or a frosted screen. The invention relates to a method of imaging a human or animal bode using a nanocrystal array capable of fluorescing upon excitation from light from a near-infrared light source. This invention also relates to detection means and apparatus used in said methods, as well as to quantum dots useful in said use.
Methods of treating and preventing Alport syndrome through inhibiting interleukin 11 (EL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
93.
THIN, FLEXIBLE WEARABLE IMMUNOSENSOR FOR DETECTION OF MULTIPLE BIOMARKERS/TARGETS IN BODILY FLUIDS
A layered dressing includes: a permeable wound contact layer for placing in contact with a wound; a breathable barrier layer; a biosensor sensing array configured to detect one or more markers in wound fluid; and a fluid collection layer disposed between the wound contact layer and breathable barrier layer and configured to deliver wound fluid by capillary action from a wound in contact with the wound contact layer to the biosensor sensing array.
A61F 13/00 - Bandages or dressings; Absorbent pads
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
94.
N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer
Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and/or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and/or acute respiratory distress syndrome.
Disclosed herein is a metal organic framework (MOF) having a UTSA-16 structure, where the composition comprises: from 0 to 80 mol % of the total metal in the MOF is a first metal selected from one or more of the group consisting of Cr, Mn, Fe, Ni, Cu, and Co; and from 20 to 100 mol % of the total metal in the MOF is a second metal selected from one or more of the group consisting of Cd, Mn, and Zn.
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
B01J 20/30 - Processes for preparing, regenerating or reactivating
There is provided a semi-crystalline polymer membrane, the membrane being a single-layer membrane and su-perwettable without provision of a coating or additives. There is also provided a method of forming the membrane comprising: depositing a solution on a substrate surface, the solution comprising a semi-crystalline polymer to form a nascent membrane; spraying a fluid on the nascent membrane; and immersing the nascent membrane in a non-solvent to form the semi-crystalline polymer membrane. In preferred embodiments, the fluid sprayed on the nascent membrane is selected from compressed air, water, a mixture of ethanol and water, or a solid suspension of ethanol/water/sodium chloride.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
Disclosed herein is a method of detecting the presence or absence of an analyte in a test sample, based on the use of motion resistant particle for example non-magnetic particle coated with first sensing element for the analyte and force driven particle for example superparamagnetic particle coated with a second sensing element for the analyte so as to form a motion resistant particle-analyte-force driven particle conjugate. A viscous medium is added to the mixture and a force such as magnetic force is applied to provide separation of the conjugate for quantification. Disclosed herein are also a sensing kit, a system for detecting the presence or absence of an analyte in a test sample and the use of the kit or the system thereof.
The present invention relates to a microfluidic device (100) for mixing liquids, wherein the microfluidic device (100) comprises a plurality of device inlets (110), each device inlet (110) for receiving a liquid; a chamber assembly (120) comprising a set of chamber inlets (122) in fluid communication with the device inlets (110); a mixing chamber (124) for receiving the liquids through the chamber inlets (122); and a plurality of chamber outlets (126) for communicating the liquids away from the mixing chamber (124); and a set of device outlets (130) in fluid communication with the chamber outlets (126), wherein the chamber outlets (126) are spaced around the mixing chamber (124) such that the mixing chamber (124) facilitates uniform mixing of the liquids communicating from the chamber inlets (122) to the chamber outlets (126). The invention also relates to a method of additive manufacturing a product comprising the microfluidic device as well as a liquid control system for controlling liquids in a microfluidic device.
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
Inventor
Scolnick, Jonathan
Yeo, Eugene
Hoon, Shawn
Abstract
The present invention provides methods, antibodies and kits for detecting and/or quantifying expression of both non-nucleic acid molecules, such as proteins, and nucleic acid molecules in a single sample or single cell. The antibody is covalently conjugated to an oligonucleotide, such as a single-stranded DNA molecule, which comprises an identification tag and a blocking group, such as a ddNTP or an inverted dTTP, which prevents extension of the oligonucleotide by a polymerase. The method comprises the steps of reverse transcribing the conjugated oligonucleotide and the target nucleic acid simultaneously, amplifying both transcription production, and detecting the amplicons thereof. The method is also useful for detecting and/or quantifying the number of cells in a sample expressing a given non -nucleic acid molecule (e.g. protein).
patents
